葵花药业(002737) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for the current period is ¥1,518,181,069.65, a decrease of 14.01% compared to the same period last year[6] - The net profit attributable to shareholders for the current period is ¥255,183,288.86, down 37.17% year-over-year[6] - The net profit after deducting non-recurring gains and losses is ¥237,454,340.04, reflecting a decline of 39.18% compared to the previous year[6] - The basic earnings per share for the current period is ¥0.44, a decrease of 37.14% from ¥0.70 in the same period last year[6] - The total operating revenue for the first quarter of 2024 was ¥1,518,181,069.65, a decrease of approximately 14.0% compared to ¥1,765,521,894.46 in the same period last year[26] - The net profit attributable to shareholders of the parent company was ¥255,206,220.86, down from ¥406,131,973.46, representing a decrease of about 37.1%[28] - The basic and diluted earnings per share for the first quarter were both ¥0.44, compared to ¥0.70 in the same period last year, a decline of approximately 37.1%[28] - Net profit decreased by 37.91% to ¥270,303,238.96 compared to ¥435,364,881.11 in the previous period, primarily due to a decline in revenue and increased costs from rising Chinese medicinal material prices[44] Assets and Equity - The total assets at the end of the current period amount to ¥7,146,595,311.44, representing a 3.85% increase from the end of the previous year[6] - The equity attributable to shareholders at the end of the current period is ¥5,021,155,795.83, which is a 5.41% increase compared to the previous year[6] - The total current assets increased to ¥5,087,394,714.11 from ¥4,787,964,197.21, reflecting an increase of approximately 6.3%[24] - The cash and cash equivalents at the end of the period were ¥3,496,677,467.15, up from ¥2,287,009,419.54, representing an increase of about 53.0%[24] - The inventory balance increased to ¥909,915,396.70 from ¥873,189,831.01, showing an increase of approximately 4.2%[24] - The total assets increased to ¥7,146,595,311.44 from ¥6,881,912,554.92, reflecting a growth in overall asset base[43] Cash Flow - The net increase in cash and cash equivalents for the current period is ¥1,209,972,261.26, compared to ¥451,842,275.99 in the previous year[3] - The cash flow from operating activities for the current period is ¥204,290,572.95, down 17.97% from the previous year[6] - The net cash flow from operating activities was ¥204,290,572.95, compared to ¥249,028,652.64 in the previous year, indicating a decline of approximately 17.9%[30] - Cash inflow from investment activities totaled ¥1,020,817,239.73, significantly higher than ¥252,569,927.27 in the previous year[30] - The cash outflow for purchasing fixed assets and intangible assets was ¥13,985,381.42, compared to ¥36,350,120.38 in the previous year, indicating a decrease of about 61.6%[30] - Investment activities generated a net cash flow of ¥1,006,831,858.31, a significant increase of 413.11% from ¥196,219,806.89 in the previous period, mainly due to the redemption of maturing financial products[44] - Cash and cash equivalents increased by 52.89% to ¥3,496,677,467.15 from ¥2,287,009,419.54, primarily due to the redemption of financial products during the period[50] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 32,355[52] - The largest shareholder, KuaHua Group Co., Ltd., holds 45.41% of the shares, totaling 265,200,000 shares[52] - The second-largest shareholder, Guan Yanbin, holds 6.03% of the shares, totaling 35,220,422 shares[52] - The company has not engaged in margin trading or securities lending activities by its controlling shareholders or related parties[52] Government Support and Other Income - The company received government subsidies amounting to ¥22,444,571.68 during the current period[18] - Other income rose by 42.22% to ¥23,156,203.91, primarily due to government subsidies received in the current period[44] Operational Developments - The company has made progress in product development, including the approval of a new oral suspension product[23] - The report indicates a focus on financial product management and revenue recognition strategies for future growth[50] - The company is exploring market expansion opportunities and potential mergers and acquisitions to enhance its competitive position[50] Financial Management - Financial expenses decreased by 99.69% to -¥11,113,152.12, attributed to an increase in bank interest income during the current period[44] - Credit impairment losses increased by 82.60% to -¥2,991,054.06, mainly due to provisions for bad debts[44] - The company reported a 272.37% increase in operating expenses to ¥938,184.74, primarily due to external donation expenditures[44] - The fair value change in investment income showed a significant increase of 98.35%, reaching ¥5,407,601.03, attributed to returns from financial products[44] - The cash flow from financing activities decreased by 115.39% to -¥1,015,792.56, primarily due to the absence of bank borrowings in the current period[44] Liabilities and Receivables - Trading financial assets decreased by 77.18% to ¥300,159,000.00 from ¥1,315,104,600.00, also attributed to the redemption of financial products[50] - Accounts receivable financing rose by 157.57% to ¥92,248,199.27 from ¥35,814,204.43, mainly due to an increase in collected notes[50] - Contract liabilities decreased by 47.21% to ¥156,972,360.41 from ¥297,324,795.11, primarily due to revenue recognition based on performance obligations[50]